Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer

Journal of Virology

Volumn 79, Issue 16, 2005, Pages 10247-10257

  Wapling, Johanna ^a,b   Moore, Katie L ^a   Sonza, Secondo ^a,b   Mak, Johnson ^a,b   Tachedjian, Gilda ^a,b,c  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; GAG PROTEIN; INDINAVIR; POL PROTEIN; PROTEIN P51; PROTEIN P66; PROTEIN SUBUNIT; PROTEINASE; RNA DIRECTED DNA POLYMERASE; TRYPTOPHAN; UNCLASSIFIED DRUG; VIRUS ENZYME; VIRUS PROTEIN;

ARTICLE; CELL LYSATE; CODON; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME DEGRADATION; ENZYME INHIBITION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE REPEAT; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN STABILITY; STEADY STATE; VIRION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS VIRULENCE; WILD TYPE;

CODON; DIMERIZATION; GENE PRODUCTS, GAG; HIV CORE PROTEIN P24; HIV PROTEASE; HIV-1 REVERSE TRANSCRIPTASE; INDINAVIR; MUTATION; PROTEIN PRECURSORS; VIRION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 23244448649     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.16.10247-10257.2005     Document Type: Article

References (66)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Amacker, M., and U. Hubscher. 1998. Chimeric HIV-1 and feline immunodeficiency virus reverse transcriptases: critical role of the p51 subunit in the structural integrity of heterodimeric lentiviral DNA polymerases. J. Mol. Biol. 278:757-765.
3. Baillon, J. G., N. T. Nashed, A. Kumar, S. H. Wilson, and D. M. Jerina. 1991. A leucine zipper-like motif may mediate HIV reverse transcriptase subunit binding. New Biol. 3:1015-1019.
4. Becerra, S. P., A. Kumar, M. S. Lewis, S. G. Widen, J. Abbotts, E. M. Karawya, S. H. Hughes, J. Shiloach, and S. H. Wilson. 1991. Protein-protein interactions of HIV-1 reverse transcriptase: implication of central and C-terminal regions in subunit binding. Biochemistry 30:11707-11719.
5. Bhattacharyya, G. K., and R. A. Johnson. 1997. Statistical concepts and methods. John Wiley and Sons, New York, N.Y.
6. Buxton, P., G. Tachedjian, and J. Mak. 2005. Analysis of the contribution of reverse transcriptase and integrase proteins to retroviral RNA dimer conformation. J. Virol. 79:6338-6348.
7. Chesebro, B., K. Wehrly, J. Nishio, and S. Ferryman. 1992. Macrophagetropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J. Virol. 66:6547-6554.
8. Derdeyn, C. A., J. M. Decker, J. N. Sfakianos, X. Wu, W. A. O'Brien, L. Ratner, J. C. Kappes, G. M. Shaw, and E. Hunter. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358-8367.
9. di Marzo Veronese, F., T. D. Copeland, A. L. DeVico, R. Rahman, S. Oroszlan, R. C. Gallo, and M. G. Sarngadharan. 1986. Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science 231:1289-1291.
10. Divita, G., T. Resile, and R. S. Goody. 1993. Characterization of the dimerization process of HIV-1 reverse transcriptase heterodimer using intrinsic protein fluorescence. FEBS Lett. 324:153-158.
11. Divita, G., K. Rittinger, T. Restle, U. Immendorfer, and R. S. Goody. 1995. Conformational stability of dimeric HIV-1 and HIV-2 reverse transcriptases. Biochemistry 34:16337-16346.
12. Fisher, A. G., E. Collalti, L. Ratner, R. C. Gallo, and F. Wong-Staal. 1985. A molecular clone of HTLV-III with biological activity. Nature 316:262-265.
13. Folks, T. M., K. A. Clouse, J. Justement, A. Rabson, E. Duh, J. H. Kehrl, and A. S. Fauci. 1989. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc. Natl. Acad. Sci. USA 86:2365-2368.
14. Ghosh, M., P. S. Jacques, D. W. Rodgers, M. Ottman, J. L. Darlix, and S. F. Le Grice. 1996. Alterations to the primer grip of p66 HIV-1 reverse transcriptase and their consequences for template-primer utilization. Biochemistry 35:8553-8562.
15. Gorelick, R. J., and L. E. Henderson. 1994. Human retroviruses and AIDS: analyses (part III). The Los Alamos National Laboratory, Los Alamos, N.Mex.
16. Harada, S., Y. Koyanagi, and N. Yamamoto. 1985. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 229:563-566.
17. Harrich, D., and B. Hooker. 2002. Mechanistic aspects of HIV-1 reverse transcription initiation. Rev. Med. Virol. 12:31-45.
18. Hawkes, R. 1979. General principles underlying laboratory diagnosis in viral infections, p. 34-35. In Diagnostic procedures for viral, rickettsial and chla-mydial infection, 5th ed. American Public Health Association, Washington, D.C.
19. Hehl, E. A., P. Joshi, G. V. Kalpana, and V. R. Prasad. 2004. Interaction between human immunodeficiency virus type 1 reverse transcriptase and integrase proteins. J. Virol. 78:5056-5067.
20. Henderson, L. E., M. A. Bowers, R. C. Sowder II, S. A. Serabyn, D. G. Johnson, J. W. Bess, Jr., L. O. Arthur, D. K. Bryant, and C. Fenselau. 1992. Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processing, and complete amino acid sequences. J. Virol. 66:1856-1865.
21. Hill, M., G. Tachedjian, and J. Mak. 2005. The packaging and maturation of the HIV-1 Pol proteins. Curr. HIV Res. 3:73-85.
22. Hill, M. K., M. Shehu-Xhilaga, S. M. Crowe, and J. Mak. 2002. Proline residues within spacer peptide p1 are important for human immunodeficiency virus type 1 infectivity, protein processing, and genomic RNA dimer stability. J. Virol. 76:11245-11253.
23. Hostomsky, Z., Z. Hostomska, T. B. Fu, and J. Taylor. 1992. Reverse transcriptase of human immunodeficiency virus type 1: functionality of subunits of the heterodimer in DNA synthesis. J. Virol. 66:3179-3182.
24. Jacobo-Molina, A., J. Ding, R. G. Nanni, A. D. Clark, Jr., X. Lu, C. Tantillo, R. L. Williams, G. Kamer, A. L. Ferris, P. Clark, et al. 1993. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc. Natl. Acad. Sci. USA 90:6320-6324.
25. Jacques, P. S., B. M. Wohrl, K. J. Howard, and S. F. Le Grice. 1994. Modulation of HIV-1 reverse transcriptase function in "selectively deleted" p66/p51 heterodimers. J. Biol. Chem. 269:1388-1393.
26. Jacques, P. S., B. M. Wohrl, M. Ottmann, J. L. Darlix, and S. F. Le Grice. 1994. Mutating the "primer grip" of p66 HIV-1 reverse transcriptase implicates tryptophan-229 in template-primer utilization. J. Biol. Chem. 269:26472-26478.
27. Kaplan, A. H., M. Manchester, and R. Swanstrom. 1994. The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J. Virol. 68:6782-6786.
28. Klein, J. R., and B. D. Jones. 2001. Salmonella pathogenicity island 2-encoded proteins SseC and SseD are essential for virulence and are substrates of the type III secretion system. Infect. Immun. 69:737-743.
29. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
30. Lee, T. H., F. J. Sunzeri, L. H. Totaler, B. G. Williams, and M. P. Busch. 1991. Quantitative assessment of HIV-1 DNA load by coamplification of HIV-1 gag and HLA-DQ-alpha genes. AIDS 5:683-691.
31. Le Grice, S. F., C. E. Cameron, and S. J. Benkovic. 1995. Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase. Methods Enzymol. 262:130-144.
32. Le Grice, S. F., T. Naas, B. Wohlgensinger, and O. Schatz. 1991. Subunit-selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase. EMBO J. 10:3905-3911.
33. Lindhofer, H., K. von der Helm, and H. Nitschko. 1995. In vivo processing of Pr160gag-pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T-lymphocytes. Virology 214:624-627.
34. Mak, J., A. Khorchid, Q. Cao, Y. Huang, I. Lowy, M. A. Parniak, V. R. Prasad, M. A. Wainberg, and L. Kleiman. 1997. Effects of mutations in Pr160gag-pol upon tRNA(Lys3) and Pr160gag-pol incorporation into HIV-1. J. Mol. Biol. 265:419-431.
35. Mulky, A., S. G. Sarafianos, E. Arnold, X. Wu, and J. C. Kappes. 2004. Subunit-specific analysis of the human immunodeficiency virus type 1 reverse transcriptase in vivo. J. Virol. 78:7089-7096.
36. Nilsen, B. M., I. R. Haugan, K. Berg, L. Olsen, P. O. Brown, and D. E. Helland. 1996. Monoclonal antibodies against human immunodeficiency virus type 1 integrase: epitope mapping and differential effects on integrase activities in vitro. J. Virol. 70:1580-1587.
37. Patel, P. H., A. Jacobo-Molina, J. Ding, C. Tantillo, A. D. Clark, Jr., R. Raag, R. G. Nanni, S. H. Hughes, and E. Arnold. 1995. Insights into DNA polymerization mechanisms from structure and function analysis of HIV-1 reverse transcriptase. Biochemistry 34:5351-5363.
38. Pear, W. S., G. P. Nolan, M. L. Scott, and D. Baltimore. 1993. Production of high-liter helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90:8392-8396.
39. Pettit, S. C., L. E. Everitt, S. Choudhury, B. M. Dunn, and A. H. Kaplan. 2004. Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism. J. Virol. 78:8477-8485.
40. Pettit, S. C., S. Gulnik, L. Everitt, and A. H. Kaplan. 2003. The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage. J. Virol. 77:366-374.
41. Restle, T., B. Muller, and R. S. Goody. 1990. Dimerization of human immunodeficiency virus type 1 reverse transcriptase. A target for chemotherapeutic intervention. J. Biol. Chem. 265:8986-8988.
42. Richardson, B. A., and J. Overbaugh. 2005. Basic statistical considerations in virological experiments. J. Virol. 79:669-676.
43. Shehu-Xhilaga, M., S. Ablan, D. G. Demirov, C. Chen, R. C. Montelaro, and E. O. Freed. 2004. Late domain-dependent inhibition of equine infectious anemia virus budding. J. Virol. 78:724-732.
44. Shin, C. G., B. Taddeo, W. A. Haseltine, and C. M. Farnet. 1994. Genetic analysis of the human immunodeficiency virus type 1 integrase protein. J. Virol. 68:1633-1642.
45. Sluis-Cremer, N., D. Arion, M. E. Abram, and M. A. Parniak. 2004. Proteolytic processing of an HIV-1 Pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation. Int. J. Biochem. Cell Biol. 36:1836-1847.
46. Sluis-Cremer, N., D. Arion, and M. A. Parniak. 2002. Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Mol. Pharmacol. 62:398-405.
47. Sluis-Cremer, N., G. I. Dmitrienko, J. Balzarini, M. J. Camarasa, and M. A. Parniak. 2000. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[spiro[4"-amino-2",2"-dioxo-1",- 2"-oxathiole-5",3′-[2′,5′-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthymine. Biochemistry 39:1427-1433.
48. Sluis-Cremer, N., and G. Tachedjian. 2002. Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. Eur. J. Biochem. 269:5103-5111.
49. Sonza, S., A. Maerz, N. Deacon, J. Meanger, J. Mills, and S. Crowe. 1996. Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes. J. Virol. 70:3863-3869.
50. Szilvay, A. M., S. Nornes, I. R. Haugan, L. Olsen, V. R. Prasad, C. Endresen, S. P. Goff, and D. E. Heiland. 1992. Epitope mapping of HIV-1 reverse transcriptase with monoclonal antibodies that inhibit polymerase and RNase H activities. J. Acquir. Immune Defic. Syndr. 5:647-657.
51. Tachedjian, G., H. E. Aronson, M. de los Santos, J. Seehra, J. M. McCoy, and S. P. Goff. 2003. Role of residues in the tryptophan repeat motif for HIV-1 reverse transcriptase dimerization. J. Mol. Biol. 326:381-396.
52. Tachedjian, G., H. E. Aronson, and S. P. Goff. 2000. Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase. Proc. Natl. Acad. Sci. USA 97:6334-6339.
53. Tachedjian, G., J. Radzio, and N. Sluis-Cremer. 2005. Relationship between enzyme activity and dimeric structure of recombinant HIV-1 reverse transcriptase. Proteins 60:5-13.
54. Tasara, T., M. O. Hottiger, and U. Hubscher. 2001. Functional genomics in HIV-1 virus replication: protein-protein interactions as a basis for recruiting the host cell machinery for viral propagation. Biol. Chem. 382:993-999.
55. Tasara, T., G. Maga, M. O. Hottiger, and U, Hubscher. 2001. HIV-1 reverse transcriptase and integrase enzymes physically interact and inhibit each other. FEBS Lett. 507:39-44.
56. Telesnitsky, A., and S. P. Goff. 1993. Two defective forms of reverse transcriptase can complement to restore retroviral infectivity. EMBO J. 12:4433-4438.
57. Vacca, J. P., B. D. Dorsey, W. A. Schleif, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahy, E. Roth, et al. 1994. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91:4096-4100.
58. Vogt, V. M. 1996. Morphogenesis and maturation of retroviruses, vol. 214. Springer-Verlag, Berlin, Germany.
59. Wang, J., S. J. Smerdon, J. Jager, L. A. Kohlstaedt, P. A. Rice, J. M. Friedman, and T. A. Steitz. 1994. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. Proc. Natl. Acad. Sci. USA 91:7242-7246.
60. Wei, X., J. M. Decker, H. Liu, Z. Zhang, R. B. Arani, J. M. Kilby, M. S. Saag, X. Wu, G. M. Shaw, and J. C. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
61. Wiegers, K., G. Rutter, H. Kottler, U. Tessmer, H. Hohenberg, and H. G. Krausslich. 1998. Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J. Virol. 72:2846-2854.
62. Wohrl, B. M., R. Krebs, S. H. Thrall, S. F. Le Grice, A. J. Scheidig, and R. S. Goody. 1997. Kinetic analysis of four HIV-1 reverse transcriptase enzymes mutated in the primer grip region of p66. Implications for DNA synthesis and dimerization. J. Biol. Chem. 272:17581-17587.
63. Wu, X., H. Liu, H. Xiao, J. A. Conway, E. Hehl, G. V. Kalpana, V. Prasad, and J. C. Kappes. 1999. Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. J. Virol. 73:2126-2135.
64. Wu, X., H. Liu, H. Xiao, J. A. Conway, E. Hunter, and J. C. Kappes. 1997. Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. EMBO J. 16:5113-5122.
65. Yu, Q., M. Ottmann, C. Pechoux, S. Le Grice, and J. L. Darlix. 1998. Mutations in the primer grip of human immunodeficiency virus type 1 reverse transcriptase impair proviral DNA synthesis and virion maturation. J. Virol. 72:7676-7680.
66. Zack, J. A., S. J. Arrigo, S. R. Weitsman, A. S. Go, A. Haislip, and I. S. Chen. 1990. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61:213-222.